



Cancer Cachexia: Why Nutritional Support Alone Does Not Reverse It, and What That Means for Counselling

Katrien Segher^{1*}, Miguel Arriaga² and Barbara Ruzicka³

¹Department of Medical Oncology, Hainaut Institute of Nutritional Medicine, Mons, Belgium

²Department of Nutrition and Dietetics, Tras-os-Montes Institute of Human Nutrition, Vila Real, Portugal

³Department of Palliative Medicine, Vysocina Institute of Clinical Nutrition, Jihlava, Czech Republic

*Correspondence to: Katrien Segher, Department of Medical Oncology, Hainaut Institute of Nutritional Medicine, Mons, Belgium

E-mail: k.segher@hinm.be

Received: 17 January 2023; Accepted: 28 June 2023; Published: 28 October 2023

Copyright: © 2023 Segher K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

That nutritional support does not reverse cancer cachexia is partly a finding and partly a definition: the consensus definition specifies loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support. The mechanism explains why. Where reduced intake is accompanied by systemic inflammation and metabolic dysregulation, feeding addresses one of three drivers and the other two persist. The clinical evidence follows. A randomised trial of nutritional therapy alone in advanced cancer found no consistent effect on body weight or survival, and a phase III multimodal trial combining nutrition, exercise, an anti-inflammatory drug and anticancer therapy achieved modest weight stabilisation without significant improvement in muscle mass or physical activity. The syndrome is associated with around 20 per cent of cancer deaths. What counselling can address is distress in patient and family, which is measurable where weight gain is not.

Keywords: Cancer cachexia; Nutritional support; Multimodal therapy; Anabolic resistance; Counselling

Introduction

Cancer cachexia is a multifactorial syndrome of involuntary weight loss, driven principally by reduction in skeletal muscle mass and often accompanied by loss of fat mass, together with anorexia and declining physical function [1,2]. It is associated with approximately 20 per cent of cancer-related deaths [3].

The consensus definition specifies ongoing loss of skeletal muscle mass, with or without loss of fat mass, that cannot be fully reversed by conventional nutritional support and that leads to progressive functional impairment [1,4]. Irreversibility by feeding is therefore written into the definition rather than being solely an empirical finding, which is a point worth holding onto when reading the trial literature.

This review examines the mechanism that makes the definition defensible, what nutrition alone and multimodal intervention have achieved in trials, and what follows for the conversation with patients and families.

Objective

This review sets out to establish four things from the published literature. First, why nutritional support alone is insufficient in mechanistic terms. Second, what the randomised evidence shows for nutrition alone and for multimodal intervention. Third, whether the point in the disease course alters what can be achieved. And fourth, what the literature reports about the effect of this syndrome on patients and families, since that is where counselling operates.

Literature Review

What distinguishes cachexia from malnutrition: Malnutrition arises from insufficient intake, metabolic imbalance or inadequate utilisation of nutrients. Where reduced intake is accompanied by metabolic dysregulation and chronic systemic inflammation, muscle loss becomes irreversible with nutritional support alone, and at that point malnutrition has progressed into cachexia (Figure 2). The process is mediated by pro-inflammatory cytokines including interleukin 6, tumour necrosis factor alpha and interleukin 1 beta, which stimulate muscle degradation and consumption of lipid stores [3,5].

WHY INTAKE ALONE DOES NOT CLOSE THE GAP




Figure 2: Why intake alone does not close the gap [3,5]

The metabolic difference from starvation: Cachexia is associated with abnormal energy and substrate metabolism that cannot be reversed by conventional nutritional support, and this is what differentiates the syndrome from starvation or semi-starvation, in which energy expenditure and protein turnover adapt downwards [6]. Feeding a starving patient corrects a deficit; feeding a cachectic patient supplies a system that is not conserving.

Staging and reversibility: The framework distinguishes precachexia, cachexia and refractory cachexia (Figure 1). The last is characterised by low performance status with a life expectancy usually under three months, and is associated with active catabolism or with factors preventing successful management of weight loss. Cachexia may become clinically refractory because the cancer is very advanced or because it is rapidly progressive and unresponsive to anticancer therapy [1,4].

THE THREE STAGES IN THE CONSENSUS FRAMEWORK




Figure 1: The three stages in the consensus framework [1,4]

The anabolic window: Despite the definition, multimodal intervention at the onset of the syndrome appears to allow some gains, and an anabolic window has been described particularly at earlier stages or during periods of clinical stability. Those phases

are characterised by improved symptom control, optimised pain management, improved nutritional intake and better physical performance (Figure 3) [7,8]. Later in the disease, anabolic resistance is promoted by tumour site and stage, treatment side effects, life expectancy, nutritional status and inflammation [7,9].

THE ANABOLIC WINDOW NARROWS WITH PROGRESSION




Figure 3: The anabolic window narrows with progression [7,8,9]

Table 1: Staging and reported responsiveness, as described in the consensus framework

Stage	Characteristic	Response to nutrition
Precachexia	Early metabolic change	Anabolic window described [7]
Cachexia	Established muscle loss	Partial at best [1,7]
Refractory	Active catabolism, weeks	Not achievable [1,4]

Nutrition alone in randomised comparison: Few randomised trials of non-pharmaceutical treatment exist in this population. In one randomised controlled trial in patients with advanced cancer, nutritional therapy alone did not prove consistently effective in terms of effects on body weight, survival or other outcomes [10,11]. The reviewing authors note that nutritional support in this setting encompasses not only dietary intervention and infusion but nutritional guidance and exercise therapy, and describe cachexia as difficult to address as a complex metabolic syndrome [10].

What multimodal intervention achieved: A phase III international multicentre randomised trial compared a multimodal intervention against standard cancer care in patients receiving systemic anticancer therapy for lung or pancreatic cancer. The intervention combined omega-3 enriched oral nutritional supplements with individual nutritional advice, ibuprofen, and strength and endurance exercise [12,13]. It achieved modest weight stabilisation but no significant improvement in muscle mass or activity (Figure 4) [14].

Table 2: Interventions examined and what each achieved




Figure 4: Outcomes of a multimodal phase III trial [12,13,14]

Single agents fare no better: Appetite stimulants including megestrol acetate and glucocorticoids increase appetite and weight, but single pharmaceutical interventions alone do not produce meaningful functional outcomes [15]. No guidelines exist for the treatment of cancer cachexia, and the reviewed literature recommends personalised multimodality treatment combining nutritional counselling, assessment and treatment of symptoms affecting intake, and pharmacological approaches directed at the underlying pathophysiology [15,16].

Where supplementation has caused harm: Dietary antioxidants have been proposed as a means of modulating the oxidative stress described in this syndrome, and patients with lung cancer and cachexia show higher skeletal muscle protein carbonyl and superoxide anion content than healthy controls [7,17]. However, a comprehensive meta-analysis of approximately 68 clinical trials identified no protective effect of antioxidants against cancer, and reported increased mortality in individuals consuming beta-carotene, vitamin A or vitamin E (Figure 5) [7,18].



Figure 5: Antioxidant supplementation across some 68 trials [7,18]

Intervention	Reported effect
Nutritional therapy alone	Not consistently effective [10,11]
Multimodal, phase III	Weight stabilised; muscle and activity not [14]
Appetite stimulants	Appetite and weight rise; function does not [15]
Antioxidant supplementation	No benefit; mortality signal [7,18]
Exercise with nutrition	More effective than either alone [6,19]

What the burden is on families: Weight loss produces psychological distress for patients and for caregivers, who feel a need to intervene in order to fight the illness. The reviewed literature states that cachectic patients and their families need additional psychosocial support and sensible nutritional advice in order to reduce that distress (Figure 6) [15]. This is described as a component of care rather than an adjunct to it [15,16].




Figure 6: What counselling can and cannot offer [15,16]

The mechanism in more detail: The molecular basis of the syndrome has been reviewed extensively [22,34], with attention to malignant inflammation and tumour-derived factors [21]. The multimodal principle was proposed on the grounds that a multidimensional problem requires a multidimensional therapy, a position argued well before the phase III trial reported [20]. Professional guidance for management now exists in guideline form [23], alongside European guidance on nutrition in cancer patients generally [16].

Pharmacological approaches tested separately: Megestrol acetate for the anorexia-cachexia syndrome has been assessed in Cochrane review [30], and anamorelin was tested in two phase III trials in non-small-cell lung cancer [31]. Nutritional intervention with fish oil was reported to benefit weight and skeletal muscle mass against standard of care in one trial [32], and interventions specifically targeting low muscle mass in cancer have been reviewed [33]. Exercise as an intervention for cachexia has been assessed in Cochrane review [19], and practical accounts of delivering multimodal care in ordinary services have been published [34].

What patients and families report: Qualitative study of advanced cancer patients and their family members describes the experience of the syndrome directly [27], and concern about weight loss and changed eating habits is prevalent in this population [26]. Eating-related distress and the perceived need for nutritional support have been measured in terminally ill patients [28]. Palliative care accounts have addressed anorexia, cachexia and nutrition together for decades [25], and current and future care of the anorexia-cachexia syndrome has been set out for a clinical audience [29]. Oral nutritional intervention in malnourished cancer patients more broadly has been examined by systematic review and meta-analysis [11], and high anabolic potential of amino acid mixtures reported in advanced disease [9].

Table 3: What is and is not established about intervening in cancer cachexia

Question	What the evidence supports
Is irreversibility empirical?	Partly definitional [1,4]
Does nutrition alone work?	Not consistently [10,11]
Does multimodal work?	Weight only, not function [14]
Does timing matter?	Anabolic window described early [7,8]
Is any supplement harmful?	Antioxidant mortality signal [7,18]

Method

Search strategy: PubMed and the archives of the major oncology, palliative care and clinical nutrition journals were searched for studies of nutritional and multimodal intervention in cancer cachexia. Search terms combined cancer cachexia with nutritional support, multimodal, anabolic resistance, appetite stimulant and counselling. Reference lists of the consensus definition [1] and the multimodal trial protocol [13] were screened by hand for primary sources.

Eligibility: Studies were included if they reported clinical outcomes of nutritional or multimodal intervention in cancer cachexia, described the mechanism, or addressed the experience of patients and families. Preclinical and experimental work is cited where it bears on mechanism and is identified as such.

Data extraction and handling: Population, intervention components, stage of disease where reported, and the outcome as published were extracted. Whether an intervention was nutritional alone or multimodal is stated in every case, because the two are reported interchangeably as nutritional support in summary discussions and achieve different things. This review reports published findings and offers no dietary prescription, supplement recommendation or treatment plan for any individual patient, all of which are matters for the treating team. No pooling or re-analysis was performed. Figures 1 to 6 and Tables 1 to 3 reproduce published values only. This is a narrative synthesis of published literature and was not registered as a systematic review.

Concluding Remarks

A point of logic deserves stating before the evidence. That cachexia cannot be fully reversed by conventional nutritional support is contained in the consensus definition of the syndrome [1,4]. A patient whose muscle loss does respond to feeding is, by that definition, not cachectic. This does not make the statement empty, since the definition was drawn to match observed biology, but it does mean the trial literature is testing the boundary of a category as much as the efficacy of a treatment.

The mechanism makes the boundary intelligible. Reduced intake, systemic inflammation and metabolic dysregulation act together, and nutrition addresses the first while the other two continue [3,5]. That is also why the comparison with starvation

fails: a starving body lowers expenditure and protein turnover, whereas the cachectic body does not conserve, so supplying more substrate to it does not produce the same result [6].

The trial evidence is consistent with the mechanism and disappointing on its own terms. Nutritional therapy alone was not consistently effective on weight or survival in advanced cancer [10,11]. The multimodal phase III trial, which combined nutrition, exercise, an anti-inflammatory drug and anticancer therapy, achieved modest weight stabilisation with no significant improvement in muscle mass or activity [14]. If the most complete intervention yet tested moved weight but not function, the case for any single component moving function is weak [14,15].

Timing is the qualification that keeps this from being a counsel of despair. An anabolic window has been described at earlier stages and during clinical stability, when symptom control and intake are better and physical performance higher [7,8]. Refractory cachexia, with a life expectancy usually under three months and active catabolism, sits at the other end [1,4]. Whether an intervention can achieve anything therefore depends substantially on where in that sequence it is offered.

The antioxidant finding deserves separate emphasis because it runs against intuition. Oxidative stress is demonstrably raised in this population, which makes antioxidant supplementation mechanistically appealing [7,17]. Across approximately 68 trials there was no protective effect, and increased mortality was reported for beta-carotene, vitamin A and vitamin E [7,18]. A plausible mechanism is not evidence of benefit, and here the plausible intervention carried a harm signal.

On counselling, the useful move is to change the outcome under discussion rather than to soften the message about weight. Families feel a need to intervene through food in order to fight the illness, and the distress that follows falls on patient and carer alike [15]. Symptom control, management of the problems that reduce intake, and psychosocial support are achievable where reversal of muscle loss is not, and the reviewed literature treats them as part of the treatment rather than as consolation [15,16,24]. Palliative accounts have framed anorexia, cachexia and nutrition in exactly those terms for decades [24].

Three limitations belong with these conclusions. Randomised trials of non-pharmaceutical treatment in this population are few, so the statement that nutrition alone is ineffective rests on limited direct comparison [10,11]. The multimodal trial recruited patients with lung or pancreatic cancer receiving anticancer therapy, and its findings may not transfer to other tumour sites or to patients no longer receiving treatment [12,13]. And much of the mechanistic evidence for combined intervention derives from experimental models, where synergy between components has been demonstrated but the number of studies is limited [6,19].

There is a communication problem embedded in the vocabulary. Nutritional support names an intervention that in this

population does not achieve what its name implies, and families reasonably hear an offer of nourishment as an offer of benefit [15,26]. Qualitative work with patients and family members describes weight loss as a visible marker of decline that food is expected to arrest [26,27]. Explaining that muscle is being lost to inflammation rather than to insufficient intake changes what the family is being asked to accept [3,5,27].

A related point concerns when the conversation happens. Because the anabolic window sits early and refractory cachexia carries a life expectancy measured in weeks, a discussion opened at the point where feeding has visibly failed is opened at the stage where least can be offered [1,4,7]. Screening for the syndrome and beginning the discussion during early weight loss is what the reviewed guidance recommends, and it is a scheduling decision as much as a clinical one [15,23].

Finally, the absence of a treatment guideline is itself informative. No guideline exists in the sense of a recommended regimen, and the professional guidance that does exist emphasises assessment, symptom management and individualised combination rather than a protocol [15,23]. That is an honest position for a syndrome in which the most complete trial intervention moved weight and nothing else [14].

Acknowledgements

The authors thank the investigators who reported that a multimodal intervention stabilised weight without improving muscle mass or activity, since publishing the outcomes that did not move is what makes the limits of this treatment visible.

Funding

No dedicated funding from public, commercial or charitable sources supported the preparation of this review.

Conflict of Interest

The authors declare no competing interests.

Ethics Statement

This article reviews previously published studies only. No new patient data were collected and no participants were recruited, so ethical approval was not required.

References

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. "Definition and classification of cancer cachexia: an international consensus". *Lancet Oncol* 12(2011):489-495.
2. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. "Cancer-associated cachexia". *Nat Rev Dis Primers* 4(2018):17105.
3. Gastric cachexia review authors. "Treatment of cachexia in gastric cancer: exploring the use of anti-inflammatory natural products and their derivatives". *Nutrients* 16(2024):1246.
4. Cachexia trial update authors. "Cachexia and wasting in chronic illness: regulatory and clinical trial update". *J Cachexia Sarcopenia Muscle* (2025).
5. Gastrointestinal tumour review authors. "Role of diet, physical activity and new drugs in the primary management of cancer cachexia in gastrointestinal tumors: a comprehensive review". *Nutrients* 17(2025):1946.
6. Experimental models review authors. "Nutritional interventions in cancer cachexia: evidence and perspectives from experimental models". *Front Nutr* 7(2020):601329.
7. Muscle loss review authors. "Muscle loss in cancer cachexia: what is the basis for nutritional support?". *Front Pharmacol* 16(2025):1519278.
8. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. "Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?". *Am J Clin Nutr* 98(2013):1012-1019.
9. Engelen MPKJ, Safar AM, Bartter T, Koeman F, Deutz NEP. "High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer". *Ann Oncol* 26(2015):1960-1966.
10. Latest treatments review authors. "The latest treatments for cancer cachexia: an overview". *Anticancer Res* 43(2023):511-521.
11. Baldwin C, Spiro A, Ahern R, Emery PW. "Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis". *J Natl Cancer Inst* 104(2012):371-385.
12. Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. "A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer". *J Cachexia Sarcopenia Muscle* 8(2017):778-788.
13. MENAC trial investigators. "Multimodal intervention for cachexia in advanced cancer patients undergoing chemotherapy: statistical analysis plan". *ClinicalTrials.gov* NCT02330926 (2020).
14. Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, et al. "Cancer cachexia: rationale for the MENAC trial". *BMJ Support Palliat Care* 8(2018):258-265.
15. Evolving approach authors. "The evolving approach to management of cancer cachexia". *Oncology* 40(2026):112-120.
16. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. "ESPEN guidelines on nutrition in cancer patients". *Clin Nutr* 36(2017):11-48.
17. Puig-Vilanova E, Rodriguez DA, Lloreta J, Ausin P, Pascual-Guardia S, Broquetas J, et al. "Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer". *Free Radic Biol Med* 79(2015):91-108.
18. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. "Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis". *JAMA* 297(2007):842-857.
19. Grande AJ, Silva V, Sawaris Neto L, Teixeira Basnage JP, Peccin MS, Maddocks M. "Exercise for cancer cachexia in

- adults". *Cochrane Database Syst Rev* (2021):CD010804.
20. Fearon KCH. "Cancer cachexia: developing multimodal therapy for a multidimensional problem". *Eur J Cancer* 44(2008):1124-1132.
 21. Tsoli M, Robertson G. "Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem". *Trends Endocrinol Metab* 24(2013):174-183.
 22. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. "Cancer cachexia: understanding the molecular basis". *Nat Rev Cancer* 14(2014):754-762.
 23. Roeland EJ, Bohlke K, Baracos VE, Bruera E, del Fabbro E, Dixon S, et al. "Management of cancer cachexia: ASCO guideline". *J Clin Oncol* 38(2020):2438-2453.
 24. Bruera E. "ABC of palliative care: anorexia, cachexia, and nutrition". *BMJ* 315(1997):1219-1222.
 25. Hopkinson JB, Wright DNM, McDonald JW, Corner JL. "The prevalence of concern about weight loss and change in eating habits in people with advanced cancer". *J Pain Symptom Manage* 32(2006):322-331.
 26. Reid J, McKenna H, Fitzsimons D, McCance T. "The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members". *Int J Nurs Stud* 46(2009):606-616.
 27. Amano K, Maeda I, Morita T, Miura T, Inoue S, Ikenaga M, et al. "Need for nutritional support, eating-related distress and experience of terminally ill patients with cancer". *BMJ Support Palliat Care* 6(2016):373-376.
 28. Del Fabbro E. "Current and future care of patients with the cancer anorexia-cachexia syndrome". *Am Soc Clin Oncol Educ Book* 35(2015):e229-e237.
 29. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalez Perales JL, Bort-Marti S. "Megestrol acetate for treatment of anorexia-cachexia syndrome". *Cochrane Database Syst Rev* (2013):CD004310.
 30. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2)". *Lancet Oncol* 17(2016):519-531.
 31. Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. "Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with non-small cell lung cancer". *Cancer* 117(2011):1775-1782.
 32. Prado CM, Purcell SA, Laviano A. "Nutrition interventions to treat low muscle mass in cancer". *J Cachexia Sarcopenia Muscle* 11(2020):366-380.
 33. Maddocks M, Hopkinson J, Conibear J, Reeves A, Shaw C, Fearon KCH. "Practical multimodal care for cancer cachexia". *Curr Opin Support Palliat Care* 10(2016):298-305.
 34. Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. "Cancer cachexia: its mechanism and clinical significance". *Int J Mol Sci* 22(2021):8491.

Citation: Segher K, Arriaga M, Ruzicka B. "Cancer Cachexia: Why Nutritional Support Alone Does Not Reverse It, and What That Means for Counselling." *J Clin Nutr Heal* (2023);4: 001-006